Touch Brain

About

Funding history · 1 round · — total

Q&A

What is the primary focus of Touch Brain's technology?

Touch Brain focuses on developing novel formulations of existing drugs for intranasal administration to treat large-market central nervous system diseases, particularly Parkinson's Disease.

When was Touch Brain founded?

Touch Brain was founded in February 2017.

What is the current operational status of Touch Brain?

Touch Brain is currently inactive and ceased to operate in January 2019.

How many employees did Touch Brain have?

Touch Brain had 1-10 employees.

What was Touch Brain's last known funding activity?

In November 2017, Touch Brain received funding from Youdim Pharmaceuticals.

What sector did Touch Brain operate in?

Touch Brain operated in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

What is the main advantage of Touch Brain's intranasal drug delivery method?

The intranasal route offers advantages such as increased bioavailability, elimination of first-pass metabolism, improved brain targeting, convenience, and better patient compliance.

Sectors & technology

Tags